Tyra’s SURF302 Data Missed the Street’s 70% CR Bar
60 mg delivered 79% ORR and clean chronic-dosing safety, but 57% CR and a new 70 mg cohort missed the Street’s bar.
/ 1647 items
#XY↓
Sagimet Gets Wall Street Upgrade After China Acne Data and U.S. Trial Clearance
Barclays says Sagimet’s dermatology-first plan is smart. China data may de-risk the U.S. Phase 3 readout expected by the end of 2027.
Novartis Failure Raises Questions for Dyne’s 2027 DM1 Readout
Novartis’ DM1 trial miss hit Dyne. JPMorgan cut DYN to Underweight with a $10 target; Stifel and Jefferies stay Buy.
Evommune Shares Slide After Second Mid-Stage Miss for Oral Eczema Drug
The company will not advance the drug in eczema and shifts focus to EVO301.
Oppenheimer Lifts Pharvaris Target to $75 After Oral HAE Pill Cuts Attacks by 83%
Oral deucrictibant XR met all endpoints; FDA filing eyed for H1 2027.
Positive Readouts, High Bar: Why the Market Faded GPCR
Phase 3 is years away, GI side effects appeared at active amylin doses, and the oral GLP-1 bar is already high.